Sox4 is required for survival, progression, and proliferation in pre-B acute lymphoblastic leukemia. 
Introduction
The Sox4 (SRY-related HMG-box) transcription factor is expressed in early B-and T-cell development similar to LEF1. In the absence of Sox4, B-cell development is arrested at the pro-B to pre-B cell transition. In Sox4 mice, pro-B cells fail to proliferate in response to IL7 and to expand and differentiate past the pre-B cell receptor checkpoint. Interestingly, SOX4 functions as transcription factor yet closely interacts with membrane-proximal cytokine receptor signaling. The PDZ domain-containing adaptor protein syntenin (SDCBP) recruits the Sox4 protein directly to the cytoplasmic tail of the IL5Rα chain. With regard to its receptor-proximal activation, Sox4
resembles the SMAD and STAT transcription factors. In addition to its IL5Rα interaction, Sox4/syntenin associates with the cytoplasmic tails of other transmembrane receptors, including syndecans and ephrins. Because IL5Rα signaling is dispensable for early B-cell development, the receptor system that recruits syntenin-mediated activation of Sox4 in early B-cell development remains to be identified.
A role for Sox4 in acute myeloid leukemia was proposed based on the identification of viral insertions, activating Sox4 expression in leukemias developing in mice carrying endogenous retroviruses. Overexpression of Sox4 was also found to block differentiation of myeloid progenitor cells. Importantly, Sox4 overexpression causes myeloid leukemia and thereby cooperates with haplo-insufficiency of the myeloid differentiation factor PU.1. In acute lymphoblastic leukemia (ALL), we found SOX4 was strongly up-regulated on tyrosine kinase inhibitor (TKI) treatment and high expression of SOX4 correlates with poor clinical outcome of patients with ALL. However, the role of Sox4 in ALL cells remains unclear. In this study, using a conditional Sox4 knockout mouse model, we showed that the deletion of Sox4 compromised proliferation and viability of leukemia cells and that SOX4 plays as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL. Current Issue First Edition Topics Collections All Issues Abstracts 1mM sodium pyruvate, 100 IU/mL penicillin and 100 mg/mL streptomycin. Human ALL cell lines were maintained in RPMI with GlutaMAX (Invitrogen) containing 20% FBS, 100 IU/mL penicillin, and 100 mg/mL streptomycin. Mouse BCR-ABL1 transformed pre-B cells were cultured in IMDM (Invitrogen) with GlutaMAX containing 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 50μM β-mercaptoethanol. Normal mouse pre-B cells were cultured in the presence of 10 ng/mL IL7.
Colony forming assay
The methylcellulose colony-forming assays were performed with 10 000 BCR-ABL1-transformed mouse pre-B ALL cells. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm diameter dishes, with an extra water supply dish to prevent evaporation. After 7 to 22 days, colony numbers were counted.
Quantitative RT-PCR Total RNA from cells was extracted using RNeasy isolation kit from QIAGEN. cDNA was generated using a poly(dT) oligonucleotide and the 
Single-locus quantitative ChIP and ChIP-on-chip analysis
ChIP assays were performed with modifications as described. Briefly, 1 × 10 human pre-B cells were cross-linked with 1%
formaldehyde. After sonication by a Q700 (Qsonica), immunoprecipitations were performed using 5 μg Sox4 or control IgG antibody.
Complexes were washed with low and high salt buffers, eluted, and reverse-crosslinked, and the DNA was precipitated.
Immunoprecipitated DNA sequences were analyzed by qPCR (Antibodies and primer sequences used for qChIP analyses are listed in supplemental Tables 2C and 1, respectively). TEAD2 and SPI1 were used as a negative control, whereas LCK and an up-stream regulatory of SPI1 were used as a positive control. SOX4 ChIP-on-Chip was performed in the prostate cancer cell line (LNCaP) in triplicates for SOX4-YFP and in duplicates for YFP empty vector control (GSE11874). Briefly, the Sox4 ChIP and input from each sample were Cy3/Cy5 fluorescent labeled and cohybridized to NimbleGen 25K human promoter array set (2 microarrays that tile 4000 bp upstream and 750 bp downstream of the transcription start site of a gene promoter on average). Raw hybridization data were Z-score normalized, and ratios of ChIP to input DNA were determined for each sample. In the enrichment plots, the ratios of ChIP versus Input in the gene promoter regions were shown for the 3 replicates of Sox4 and for the 2 replicates of control, respectively, and the horizontal lines represent the 95 percentile of the ratios of ChIP to input for Sox4 and control samples, respectively.
Western blotting
Cells were lysed in CelLytic buffer (Sigma-Aldrich) supplemented with 1% protease inhibitor cocktail (Pierce), 1% phosphatase inhibitor cocktail (Calbiochem), and 1mM PMSF. Protein samples were loaded on NuPAGE (Invitrogen) 4% to 12% Bis-Tris gradient gels and transferred on polyvinylidene difluoride membranes (Invitrogen). For the detection of mouse and human proteins by Western blot, primary antibodies were used together with the WesternBreeze immunodetection system (Invitrogen). The antibodies used for Western blotting are listed in supplemental Table 2B .
Flow cytometry
Approximately 1 million cells/sample were resuspended in PBS blocked using Fc blocker for 10 minutes on ice, followed by staining with the appropriate dilution of the antibodies for 15 minutes on ice. Cells were washed and resuspended in PBS with PI (0.2 μg/mL) as a dead cell marker. The antibodies used for flow cytometry are listed in supplemental Table 2 . For annexin V staining, annexin V binding buffer (BD Bioscience) was used instead of PBS and 7AAD (BD Bioscience) instead of PI. PE labeled annexin V was purchased from BD Bioscience.
For BrdU staining, the BrdU Flow Kit was purchased from BD Bioscience and performed according to the manufacturer's protocol. 
Survival analysis
Kaplan-Meier survival analysis was used to estimate overall survival (OS). Basically, patients with B-ALL (COG clinical trial, P9906, n = 207)
were segregated into 2 groups according whether they had more than or less than the median expression level of the SOX4 probe-set.
Log rank test was used to compare survival differences between patient groups. R package "survival" Version 2. Absence of Sox4 leads to loss of self-renewal capacity and failure to form colonies in 3 serial replatings ( Figure 2C ).
Figure 1
Up-regulat io n o f SOX4 in respo nse t o TKI t reat ment in Ph ALL. Ph ALL (BV173, SUP-B15, TOM1, and NALM1; supplemental Table 6 ) and murine pre-B ALL were treated with the tyrosine kinase inhibitor (TKI) Imatinib for 16 hours (IM; A). Based on gene expression analyses we identified SOX4 as a gene that is highly up-regulated. BCR-ABL1-transformed mouse pre-B ALL cells were treated with or without Imatinib (IM; 2μM) for 16 hours and mRNA levels of SOX4 were measured by quantitative RT-PCR (B). In panel C, 3 human Ph ALL cell lines were treated with or without Imatinib (IM; 2μM) for 16 hours and SOX4 protein levels were assayed by Western blot using β-actin as loading control. 
Mechanism of Sox4-mediated survival signaling in ALL
To study the mechanism of Sox4 regulation in pre-B ALL, we performed a loss-of-function gene expression array experiment ( Figure   3A ). Deletion of Sox4 reduced mRNA levels of multiple genes that play a known role in survival signaling in Ph ALL cells including Bcl2l1 enrichment by ligation-mediated PCR [HELP] assay) revealed lower levels SOX4 promoter methylation in human Ph ALL cells compared with their normal pre-B cell counterparts ( Figure 6C ). In addition, samples from patients with high risk ALL (n = 31) show a trend toward higher SOX4 mRNA levels compared with patients with intermediate risk ALL (n = 23, P = .07, Figure 6D ; ALL REZ BFM 2002, GSE4698).
Analyzing data from a larger study based on 207 patients with ALL (COG P9906) showed a statistically significant association between high mRNA levels of SOX4 and poor clinical outcome (shorter overall survival; Figure 6E and supplemental Figure 8 ).
Figure 6
So x4 pro mo t es leukemic t ransfo rmat io n in vivo and is co rrelat ed wit h po o r clinical o ut co me. Sox4 ALL cells were transduced with 4-OHTinducible Cre or an empty vector control (EV) and labeled with firefly luciferase. One × 10 cells were injected into sublethally irradiated (2.5 Gy) NOD/SCID mice and leukemic expansion was tracked by luciferase bioimaging (A). In panel B overall survival of transplant recipient mice is shown in a Kaplan-Meier analysis (7 mice per group; P = .0007). The methylation status of the SOX4 promoter was studied (HELP assay ; C) in normal human bone marrow pre-B cells (n = 12) and bone marrow biopsies of human Ph ALL (n = 83; P = 1.5 ×10 ; data from ECOG E2993 and ECOG leukemia tissue bank). In panel D, samples from patients with high risk ALL (n = 31) are compared with patients with intermediate risk ALL in relation to their SOX4 mRNA levels (n = 23, P = .07; ALL REZ BFM 2002, GSE4698). In panel E, we analyzed clinical and gene expression data from the pediatric ALL trial COG P9906 (GSE36543). Samples from 207 patients were divided into 2 groups according to higher (red curve; n = 103) or lower (green; n = 104) than mean expression of Sox 4 among all patients. The Kaplan-Meier analysis of overall survival shows a significant difference between the 2 groups (P = .046; H). 
Discussion
In this study, we identified Sox4 as a critical factor in survival signaling of Ph ALL. Sox4 regulates survival via Bcl-xL, Mapk8 (JNK1) and genes of the PI3K/AKT pathway. A recent study based on pharmacologic targeting of the PI3K/AKT downstream signaling highlighted the relevance of this pathway in human Ph ALL. The BCR-ABL1 oncogene has been shown to activate the JNK pathway and disruption of Mapk8 (JNK1) results in defective transformation of BCR-ABL1 driven pre-B ALL. In Ph leukemia, Bcl-xL represents an important survival molecule and Stat5-dependent transcriptional activation of Bcl-xL promotes inhibition of apoptosis. Therefore, the discovery of SOX4 as a critical upstream regulator to enable Bcl-xL, JNK1, and PI3K/AKT signaling in Ph ALL represents an important finding. The specific rescue by Bcl-xL and active mutants of AKT or PI3K of loss of viability on Sox4 deletion provides mechanistic evidence that Sox4 regulates leukemia cell survival through these components ( Figure 5D -E, supplemental Figure 7 ). In addition, Sox4 negatively regulates p53/Arf (Figure 5B-C) . Because our ChIP analyses did not reveal direct binding of Sox4 at CDKN2A (arf) and TP53 (p53) promoters, these effects may be indirect, for example, mediated via PI3K/AKT. Given that Arf and p53 represent critical negative regulators of self- 
